PubMed Health⌕ Search

Biomedical subjects

K I Wada

Publications and source records attributed to K I Wada.

2 recordsLinked to original sources

Natural occurrence of myofiber cytoplasmic enlargement accompanied by decrease in myonuclear number.

It has been shown that changes in the nuclear number in myofibers are synchronized with myofiber size. Therefore, under some conditions, the myonuclear number is thought to be a determinant factor of myofiber size. However, we have clearly shown that denervation-induced fiber atrophy occurs without any decrease in myonuclear number, indicating that the myonuclear number is not always an important determinant factor of myofiber size. However, this was an event found under experimental conditions. In the present study, we examined the morphological features of single myofibers under normal conditions throughout the lifespan of normal mice. We discovered that the C/N ratio (cell volume/nucleus) greatly increases during the growth period and clearly decreases during the aging period. From 5 weeks to 6 months old, the myofibers undergo fiber hypertrophy accompanied by a decrease in myonuclear number. In muscle at 18 months, we found no correlation between myonuclear number and fiber cross-sectional area. These results suggest that, even under normal physiological conditions, the myonuclear number is not always a determinant factor of the myofiber size.

Age Factors↗

Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.

The biochemical and pharmacological profile of YM087, 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin- 6-yl)-carbonyl]-2-phenylbenzanilide monohydrochloride, a newly synthesized nonpeptide vasopressin (AVP) antagonist, was investigated in several in vitro and in vivo studies. YM087 showed high affinity for V1A receptors from rat liver and V2 receptors from rat kidney with Ki values of 0.48 and 3.04 nM, respectively. YM087 also inhibited [3H]oxytocin (OT) binding to rat uterus (OT receptors) plasma membranes with a Ki value of 44.4 nM, and at 100 microM did not affect the binding of [3H]AVP to anterior pituitary (V1B receptors) plasma membranes, which indicated that it had less affinity for these OT and V1B receptors. YM087 had no effect on cytosolic free calcium concentration ([Ca++]i) itself, but suppressed AVP-induced increase in [Ca++]i of cultured vascular smooth muscle cells at the same concentrations as the binding affinities. Furthermore, YM087 potently blocked AVP-induced cAMP production of cultured renal epithelium cells concentration dependently and had no agonistic activities. In in vivo studies, intravenous administration of YM087 inhibited the pressor response to exogenous AVP in pithed rats and produced an aquaretic effect in dehydrated conscious rats in a dose-dependent manner. These results demonstrate that YM087 is a potent and nonpeptide dual AVP V1A and V2 receptors antagonist and can be used in future studies to help clarify the physiological and pathophysiological roles of AVP.

Animals↗